BriaCell raises $5.0M in registered direct offering with warrants; director participates

BriaCell Therapeutics Corp.

Gross proceeds of $5.0M from sale of 2,402,935 shares (or pre-funded warrants) and warrants for additional 2,402,935 shares.
Combined purchase price: $2.00/share for institutional investors; $2.215/share for a director of the company.
Warrants exercisable at $2.11/share, beginning 6 months from issuance, expiring in 5 years.
Net proceeds to fund working capital and Phase 3 pivotal study in advanced breast cancer.
Closing occurred May 17, 2024; placement agent A.G.P./Alliance Global Partners received 7% fee and 50,000 warrants.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

BriaCell Therapeutics Corp. entered into Securities Purchase Agreements with certain investors valued at Gross proceeds of $5,000,000 from sale of shares and warrants (effective 2024-05-14).

Action: entry
Agreement: equity purchase
Counterparty: certain investors
Value: Gross proceeds of $5,000,000 from sale of shares and warrants
Effective: 2024-05-14

Exact text from the filing

On May 14, 2024, BriaCell Therapeutics Corp. (the “Company”) entered into securities purchase agreements (the “Purchase Agreements”) with certain investors (collectively the “Purchasers”).

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

BriaCell Therapeutics Corp. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners valued at Cash fee of 7.0% of gross proceeds; Placement Agent Warrants for 50,000 shares at $2.321 per share (effective 2024-05-14).

Action: entry
Agreement: underwriting
Counterparty: A.G.P./Alliance Global Partners
Value: Cash fee of 7.0% of gross proceeds; Placement Agent Warrants for 50,000 shares at $2.321 per share
Effective: 2024-05-14

Exact text from the filing

In connection with the Offering, on May 14, 2024, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with A.G.P./Alliance Global Partners (the “Placement Agent”).

View on SEC.gov

294 material agreements filed in the last 30 days. Browse all material agreements →

BriaCell Therapeutics Corp. filing history →

Source: SEC EDGAR

accession 0001493152-24-020460

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.